Gene therapy for X-linked severe combined immunodeficiency: Historical outcomes and current status - 05/08/20
Doi : 10.1016/j.jaci.2020.05.055
Sung-Yun Pai, MD a, Adrian J. Thrasher, MB, PhD, FMedSci b, ⁎ 
a Division of Hematology-Oncology, Boston Children’s Hospital and Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Mass
b University College London Great Ormond Street Institute of Child Health, and Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom
∗Corresponding author: Adrian J. Thrasher, MB, PhD, FMedSci, Great Ormond Street Institute of Child Health, University College London, 30 Guilford St, London WC1N 1EH, UK.FMedSciGreat Ormond Street Institute of Child HealthUniversity College London30 Guilford StLondonWC1N 1EHUK
Key words : Severe combined immunodeficiency, gene therapy, T cell, B cell
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| A.J.T. is supported by funding from The Wellcome Trust (grant no. 217112/Z/19/Z AJT) and the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. |
|
| Disclosure of potential conflict of interest: S.-Y. Pai is employed by Boston Children’s Hospital and has received funding from the National Institutes of Health. A. J. Thrasher is a cofounder of Orchard Therapeutics (www.orchard-tx.com/.) |
Crown Copyright © 2020
Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 146 - N° 2
P. 258-261 - Agosto 2020 Ritorno al numero
Articolo precedente
- News Beyond Our Pages
- Marc E. Rothenberg, Jean Bousquet
- Gene therapy for Wiskott-Aldrich syndrome: History, new vectors, future directions
- Francesca Ferrua, Francesco Marangoni, Alessandro Aiuti, Maria Grazia Roncarolo
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?